<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title xml:lang="en">Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3195026</article-id><article-id pub-id-type="pmcid-ver">PMC3195026.1</article-id><article-id pub-id-type="pmcaid">3195026</article-id><article-id pub-id-type="pmcaiid">3195026</article-id><article-id pub-id-type="pmid">21844314</article-id><article-id pub-id-type="doi">10.1128/AAC.00068-11</article-id><article-id pub-id-type="publisher-id">0068-11</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Efficacy of Human-Simulated Exposures of Tomopenem (Formerly CS-023) in a Murine Model of <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content> and Methicillin-Resistant <named-content content-type="genus-species">Staphylococcus aureus</named-content> Infection<xref ref-type="fn" rid="FN1"><sup>&#9663;</sup></xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sugihara</surname><given-names initials="K">Kiyoshi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tateda</surname><given-names initials="K">Kazuhiro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamamura</surname><given-names initials="N">Naotoshi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koga</surname><given-names initials="T">Tetsufumi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sugihara</surname><given-names initials="C">Chika</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names initials="K">Keizo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Biologics Research Laboratories, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan</aff><aff id="aff2"><label>2</label>Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan</aff><aff id="aff3"><label>3</label>Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan</aff><aff id="aff4"><label>4</label>Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Mailing address: 
<addr-line>Biologics Research Laboratories, Daiichi Sankyo Co., Ltd., 16-13, 1-Chome Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan</addr-line>. Phone: 
<phone>81-3-5696-3915</phone>. Fax: 
<fax>81-3-5696-4264</fax>. E-mail: <email>sugihara.kiyoshi.mv@daiichisankyo.co.jp</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2011</year></pub-date><volume>55</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">201205</issue-id><fpage>5004</fpage><lpage>5009</lpage><history><date date-type="received"><day>18</day><month>1</month><year>2011</year></date><date date-type="rev-request"><day>20</day><month>5</month><year>2011</year></date><date date-type="accepted"><day>26</day><month>7</month><year>2011</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2012</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2012</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2013-03-28 12:12:26.627"><day>28</day><month>03</month><year>2013</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2011, American Society for Microbiology. All Rights Reserved.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zac5004.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="zac01111005004.pdf"/><abstract><p>Tomopenem (formerly CS-023) is a novel carbapenem with improved activity against diverse hospital pathogens, including <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content> and methicillin-resistant <named-content content-type="genus-species">Staphylococcus aureus</named-content> (MRSA), and has a half-life about twice longer than the half-lives of other carbapenems such as imipenem and meropenem. Our objective in this study was to estimate the efficacy of tomopenem in humans by human-simulated exposures in a neutropenic murine thigh infection model against 9 clinical isolates of <named-content content-type="genus-species">P. aeruginosa</named-content> with MICs of 4 to 32 &#956;g/ml and 9 clinical isolates of MRSA with MICs of 4 to 16 &#956;g/ml. Human-simulated dosing regimens in neutropenic mice were designed to approximate the cumulative percentage of a 24-h period that the free drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (<italic>f</italic>%<italic>T</italic><sub>MIC</sub>) observed with tomopenem at 750 and 1,500 mg given as a 0.5-h infusion three times a day (TID) in humans. As reported previously, there was no difference between the target values of <named-content content-type="genus-species">P. aeruginosa</named-content> and MRSA required for efficacy (K. Sugihara et al., Antimicrob. Agents Chemother. <bold>54:</bold>5298-5302, 2010). Tomopenem at 750 mg showed bactericidal or bacteriostatic effects against 10 of 11 strains of <named-content content-type="genus-species">P. aeruginosa</named-content> and MRSA with MICs of &#8804;8 &#956;g/ml (<italic>f</italic>%<italic>T</italic><sub>MIC</sub> &#8805; 41), and tomopenem at 1,500 mg showed bactericidal effects against 16 of 17 strains of <named-content content-type="genus-species">P. aeruginosa</named-content> and MRSA with MICs of &#8804;16 &#956;g/ml (<italic>f</italic>%<italic>T</italic><sub>MIC</sub> &#8805; 43). Meropenem at 1,000 mg TID was tested for comparison purposes and showed bactericidal or bacteriostatic effects against 3 of 4 strains of <named-content content-type="genus-species">P. aeruginosa</named-content> with MICs of &#8804;4 &#956;g/ml (<italic>f</italic>%<italic>T</italic><sub>MIC</sub> &#8805; 33). From these results, tomopenem is expected to be effective with an <italic>f</italic>%<italic>T</italic><sub>MIC</sub> of over 40 against <named-content content-type="genus-species">P. aeruginosa</named-content> and MRSA strains with MICs of &#8804;8 &#956;g/ml at doses of 750 mg TID and strains with MICs of &#8804;16 &#956;g/ml at doses of 1,500 mg TID.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>